US Stock Movement | Hims & Hers Health rises more than 2% pre-market, Novo Nordisk's flagship weight loss drug to launch on the platform

LootboxPhobia · 2026-03-10T12:08:37+00:00

American telehealth company Hims & Hers Health saw its stock price surge over 40% after partnering with Novo Nordisk to sell weight-loss drugs Ozempic and Wegovy. Novo Nordisk will offer the medications at lower prices through the Hims platform and withdraw patent infringement lawsuits.

LootboxPhobia

2026-03-10 12:08:37

Abstract generation in progress

Gelonghui, March 10 — U.S. internet healthcare company Hims & Hers Health (HIMS.US) surged over 40% on Monday, continuing to rise by 2.3% in pre-market trading today to $22.67. According to news, Novo Nordisk announced that it will sell its flagship weight-loss drugs through the Hims platform to American consumers and will simultaneously withdraw the patent infringement lawsuit filed last month. Under the agreement, Hims will provide Ozempic, Wegovy injections, and Wegovy oral tablets to U.S. consumers at Novo Nordisk’s self-pay prices. Previously, Novo Nordisk significantly reduced the monthly cost of its weight-loss drugs from about $1,000 to a range of $149 to $299. (Gelonghui)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes